Xarelto Litigation Settles for $775 Million
March 25, 2019
Bayer and Johnson & Johnson agreed to resolve nationwide litigation over its blood thinner, Xarelto, for $775 million.
The litigation involves over 22,000 cases in both federal and state court. Xarelto has been linked to internal bleeding, including cerebral or gastrointestinal hemorrhage, pulmonary embolism (PE), deep vein thrombosis (DVT), and, in some instances, death. Injury victims claim that Xarelto’s manufacturers, Bayer and Johnson & Johnson, failed to provide adequate warning about the drug’s dangers.
In at least one trial, a jury agreed, awarding over $28 million to a Xarelto consumer.
What is Xarelto?
Xarelto, or Rivaroxaban, is a blood thinner that prevents blood clots in the lungs or veins. It is often prescribed following knee or hip surgeries. And, doctors often prescribe it to lower stroke risks in people who have suffered atrial fibrillation (A-Fib).
Concerned About Xarelto?
If you’re on Xarelto, and have questions about this drug, we urge you to contact your doctor. If you’ve taken the drug and suffered a cerebral or gastrointestinal hemorrhage, pulmonary embolism (PE) or deep vein thrombosis (DVT), call one of our firm’s products liability and medical device attorneys to learn about your rights.
Philadelphia Product Liability Lawyers at Galfand Berger, LLP Represent Individuals Injured by Deadly Prescriptions
If you sustained injuries or became ill as a result of this drug or other prescription drug, please contact our Philadelphia product liability lawyers at Galfand Berger. With offices located in Philadelphia, Bethlehem, Lancaster, and Reading, we serve clients throughout Pennsylvania and New Jersey. To schedule a consultation, call us at 800-222-8792 or complete our online contact form.